<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119492">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099370</url>
  </required_header>
  <id_info>
    <org_study_id>US-BGT-13-10458</org_study_id>
    <nct_id>NCT02099370</nct_id>
  </id_info>
  <brief_title>Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients</brief_title>
  <acronym>ADIMS</acronym>
  <official_title>A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen Idec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are measuring the adherence rates of an oral MS drug that is to be
      administered twice-daily. The investigators would like to observe any patterns that might
      indicate factors that greatly affect adherence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>adherence rates to Tecfidera</measure>
    <time_frame>over one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        community sample of Multiple Sclerosis patients started on Tecfidera
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent and any authorizations required by local law
             (e.g., Protected Health Information [PHI]).

          -  Aged 18 at the time of informed consent.

          -  Must have a relapsing form of MS.

          -  Male subjects and female subjects of child-bearing potential (including female
             subjects who are not post-menopausal for at least 1 year) must be willing to practice
             effective contraception (as defined by the investigator) during the study and be
             willing and able to continue contraception for 30 days after their last dose of study
             treatment.

        Exclusion Criteria:

          -  Progressive form of MS

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

          -  Female subjects considering becoming pregnant while in the study.

          -  Female subjects who are currently pregnant or breast-feeding.

          -  Unwillingness or inability to comply with the requirements of the protocol including
             the presence of any conditional (physical, mental or social) that is likely to affect
             the subject's ability to comply with the protocol.

          -  Any other reason that, in opinion of the Investigator and/or the Sponsor, the subject
             is determined to be unsuitable for enrollment in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USF Carol and Frank Morsani Center for Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Augnst, MPH</last_name>
      <phone>813-974-6378</phone>
      <email>aaungst@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Pearsall, LPN</last_name>
      <phone>813-974-9424</phone>
      <email>lpearsal@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Derrick Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise Casady, ARNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Aungst, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurie Pearsall, LPN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Derrick Scott Robertson</investigator_full_name>
    <investigator_title>MD, Multiple Sclerosis Center Director</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Tecfidera(R)</keyword>
  <keyword>Oral medication</keyword>
  <keyword>Adherence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dimethyl fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
